Pfizer and BioNTech announce data demonstrating high immune response after a COVID booster in children ages 5 through 11
April 14, 2022 – Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster…